Estimating Hypothetically Negotiated Royalty Rates After MedImmune, Inc. v Genentech, Inc. et al
$25.00v14i3: pp. 43-52 Stenan D. Porter Antitrust 2008
Showing all 2 results
v14i3: pp. 43-52 Stenan D. Porter Antitrust 2008
v7i3: pp. 35-44 Susan G Christoffersen; Creighton Frampton Earnings Growth| Fringe Benefits 1997-1998
No products in the cart.